The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
about
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy.Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.Prognostic impact of a novel gene expression profile classifier for the discrimination between metastatic and non-metastatic primary colorectal cancer tumors.Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.POLE somatic mutations in advanced colorectal cancer.Exome analysis of carotid body tumor.Molecular profiling and sequential somatic mutation shift in hypermutator tumours harbouring POLE mutations.Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNASuccessful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
P2860
Q38648300-E258088F-6D34-4EF1-AEDD-E555CE16A8D8Q38930244-8188FF8A-AF6D-4ABB-B59A-8BA5B81B2353Q39421725-97D9B8C0-BD5F-485C-BF27-76215DF2E516Q46364204-C86435BA-6388-43D7-9B12-D02486FB9B6EQ47125672-1C22040D-49CE-4333-B568-9FD1A7D578B7Q47862144-18649980-2D20-420B-9813-AC1359C72F75Q47862551-018FE395-E54A-47C5-841B-CD917BAE4468Q48125044-1821DBEF-C8E0-4619-AEC3-03B1985CD3A9Q52674249-B4BD5AFE-2F2C-4113-8FF8-B1D0B2FC9AB9Q55448998-70492802-7C3C-4CA0-9AF5-9B2E1B8165B9Q57824704-BD57BFE0-C136-4920-8396-CC389EE87CF3Q59127261-A16DB498-B355-4421-8E64-15A2AFE743A8
P2860
The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The somatic POLE P286R mutatio ...... c biomarker for immunotherapy.
@en
The somatic POLE P286R mutatio ...... c biomarker for immunotherapy.
@nl
type
label
The somatic POLE P286R mutatio ...... c biomarker for immunotherapy.
@en
The somatic POLE P286R mutatio ...... c biomarker for immunotherapy.
@nl
prefLabel
The somatic POLE P286R mutatio ...... c biomarker for immunotherapy.
@en
The somatic POLE P286R mutatio ...... c biomarker for immunotherapy.
@nl
P2093
P2860
P921
P356
P1433
P1476
The somatic POLE P286R mutatio ...... ic biomarker for immunotherapy
@en
P2093
Adnan Ahmad Ansari
Chang-Sik Yu
Deokhoon Kim
Se Jin Jang
Tae Won Kim
P2860
P304
68638-68649
P356
10.18632/ONCOTARGET.11862
P407
P577
2016-10-01T00:00:00Z